Alexion, AstraZeneca Rare Disease’s Ultomiris (ravulizumab) has been approved in the US to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. This indication… read more.
Travere Therapeutics, Inc. presented new biomarker data from the Phase 3 PROTECT Study providing evidence that FILSPARI (sparsentan) may modify the underlying disease pathophysiology in people with IgA… read more.
Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, announced (12th October 2026) that interim results from its V012… read more.
The risk of community-acquired acute kidney injury (AKI) is higher in the summer months according to an analysis of Japanese health insurance data – especially among young people…. read more.
Acute kidney injury (AKI) is a common and severe complication in the intensive care unit (ICU). Due to its high incidence, strong correlation with poor prognosis, and substantial… read more.
Nephrotic syndrome is caused when the filtering system in the kidneys is damaged, allowing large amounts of protein to leak into the urine. It is usually treated with… read more.
Chronic kidney disease (CKD) is currently ranked the ninth leading cause of death globally[1]. However, up to half of the cases may remain undetected despite the availability of… read more.
MannKind Corporation announced that the FDA has approved Furoscix ReadyFlow (furosemide injection) for the treatment of edema (fluid overload) in adults with heart failure (HF) or chronic kidney… read more.
Novartis announced that the FDA has granted traditional approval for Fabhalta (iptacopan) to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) at risk of… read more.
Nearly half of Americans with kidney failure who are referred for transplantation never begin the process required to be considered for a new organ, a new study shows,… read more.
Novartis reported final 2.5-year Phase III ALIGN results showing slower kidney function decline with Vanrafia (atrasentan) versus placebo in adults with IgA nephropathy (IgAN). Results were published in The… read more.
BD (Becton, Dickinson and Company) announced the introduction of the Elyra Thulium Fiber Laser (TFL) System, an advanced laser platform developed to complete BD’s kidney stone care portfolio… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
